ResMed Inc. 10-Q Summary: Quarter Ended September 30, 2003
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for ResMed Inc., a Delaware corporation designing, manufacturing, and marketing devices for sleep-disordered breathing (primarily obstructive sleep apnea). The reporting period covers the three months ended September 30, 2003. The company operates manufacturing facilities in Australia, Germany, and the United States, with major distribution sites globally.
Key Financial Metrics
| Metric (in thousands, except per share) | Q3 2003 | Q3 2002 |
|---|---|---|
| Net Revenue | $72,878 | $58,586 |
| Gross Profit | $47,158 | $37,697 |
| Gross Margin | 64.7% | 64.3% |
| Operating Income | $18,954 | $15,511 |
| Net Income | $12,249 | $9,571 |
| Diluted EPS | $0.35 | $0.28 |
| Cash from Operations | $12,568 | $8,050 |
| Cash & Equivalents (End of Period) | $104,677 | $73,570 |
| Convertible Debt Outstanding | $113,250 | $113,250 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 24% ($14.3 million) year-over-year, driven by higher unit sales of flow generators and accessories. International currency appreciation contributed approximately $3.9 million to the increase.
- Profitability: Net income rose 28% to $12.2 million. Gross margin improved slightly to 65% due to a favorable product mix and improved margins at the German subsidiary (MAP), partially offset by higher Australian manufacturing costs due to currency fluctuations.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 25% ($4.4 million), largely due to increased personnel and currency effects. Research and development (R&D) expenses rose 37% ($1.6 million) due to increased staffing and clinical trial costs.
- Liquidity: Cash and cash equivalents decreased by $9.8 million during the quarter, primarily due to significant investing activities ($31.9 million used), including $11.0 million in capital expenditures for a new manufacturing facility and purchases of marketable securities.
Outlook, Risks, and Unusual Items
- Legal Settlements: ResMed settled two significant patent infringement lawsuits (one with Respironics and one with Fisher & Paykel Healthcare) during the quarter. All claims were dismissed with prejudice.
- Acquisitions: The company acquired the assets of Respro Medical Company Limited (Hong Kong distributor) for $184,000 in cash, recording $89,000 in goodwill.
- Capital Projects: Significant capital expenditures ($11.0 million) were directed toward the construction of a new manufacturing facility in Sydney, Australia, expected to be operational in the first half of calendar 2004.
- Risks: Key risks include foreign currency exchange rate fluctuations (significant exposure to Australian Dollar and Euro), reliance on third-party reimbursement, regulatory approvals (FDA), and competition. The company utilizes foreign currency option contracts to hedge these risks.
- Guidance: The filing does not provide specific numerical guidance for future periods but notes that operating results for the quarter are not necessarily indicative of full-year results.
Investor Verification Checklist
- Currency Impact: Verify the extent to which reported revenue and expense growth is driven by organic sales versus foreign currency appreciation (AUD/EUR vs. USD).
- Inventory Levels: Review the 24% increase in inventory ($56.0 million) to ensure it aligns with sales growth and the strategic build-up prior to the Australian facility relocation.
- Capital Expenditure Timeline: Confirm the progress and cost estimates for the new Sydney manufacturing facility, which is a major cash outflow driver.
- Debt Conversion: Monitor the $113.3 million in convertible subordinated notes (due 2006) and the company's ability to manage potential conversion or redemption scenarios.
- Product Pipeline: Assess the status of the "micro MESAM" diagnostic screening device, expected for release in February 2004, as a future revenue driver.